WO2011078223A1 - 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー - Google Patents
頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー Download PDFInfo
- Publication number
- WO2011078223A1 WO2011078223A1 PCT/JP2010/073129 JP2010073129W WO2011078223A1 WO 2011078223 A1 WO2011078223 A1 WO 2011078223A1 JP 2010073129 W JP2010073129 W JP 2010073129W WO 2011078223 A1 WO2011078223 A1 WO 2011078223A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lymph node
- head
- cervical lymph
- neck cancer
- expression level
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a method for analyzing cervical lymph node metastasis and a tumor marker for head and neck cancer.
- Non-Patent Documents 1 to 3 Sentinel lymph node biopsy has been used clinically for various carcinomas since Morton et al. Reported its usefulness against malignant melanoma in 1992 (Non-patent Document 4). The usefulness has already been reported (Non-patent Documents 2 and 3).
- lymph node metastasis of squamous cell carcinoma of the head and neck can be determined using QRT-PCR method based on the expression level of PVA (pemphigus vulgaris antigen) gene (Non-patent Document 9).
- Patent Documents 1 and 2 disclose tumor markers for head and neck cancer.
- Kazuhiko Sato Hoshio Hirayama et al .: sentinel lymph node biopsy: Ayumi of Acupuncture 192: 147-150,2000.
- Matsuzuka Takashi Shikano Masato et al .: Prediction of cervical lymph node metastasis by sentinel lymph node biopsy: head and neck tumor 27: 192-197, 2001.
- Junichi Kihara Naoyuki Kono et al .: Examination of sentinel lymph nodes in cases of oral cancer N0: head and neck tumor 28: 108-113, 2002.
- the present invention provides a method for analyzing cervical lymph node metastasis of head and neck cancer and a tumor marker for head and neck cancer used therefor.
- the present invention is a method for analyzing metastasis of head and neck cancer to a cervical lymph node, which is selected from the group consisting of genes represented by SEQ ID NOs: 1 to 36 in the sequence listing in a cervical lymph node sample.
- the present invention relates to a method for analyzing cervical lymph node metastasis, which comprises measuring the expression level of at least one gene and comparing the expression level with a reference value.
- the present invention includes, as an aspect thereof, one or a plurality of genes selected from the group consisting of genes represented by SEQ ID NOs: 1 to 36 in the sequence listing, or their expression products and / or expression levels.
- the present invention also relates to a tumor marker for head and neck cancer used in the method for analyzing cervical lymph node metastasis of the present invention.
- the present invention has an effect that the possibility of metastasis of head and neck cancer to cervical lymph nodes can be analyzed.
- FIG. 1 is a graph showing an example in which the expression level of the gene represented by SEQ ID NO: 6 in the sequence listing (ANXA8L2 mRNA expression level) was measured in head and neck cancer metastatic lymph nodes and normal lymph nodes.
- FIG. 2 is a graph showing an example in which the expression level of the gene represented by SEQ ID NO: 9 in the sequence listing (DSG3 mRNA expression level) was measured in head and neck cancer metastatic lymph nodes and normal lymph nodes.
- FIG. 3 is a graph showing an example in which the expression level of the gene represented by SEQ ID NO: 13 in the sequence listing (S100P mRNA expression level) was measured in head and neck cancer metastatic lymph nodes and normal lymph nodes.
- FIG. 1 is a graph showing an example in which the expression level of the gene represented by SEQ ID NO: 6 in the sequence listing (ANXA8L2 mRNA expression level) was measured in head and neck cancer metastatic lymph nodes and normal lymph nodes.
- FIG. 2 is a graph showing
- FIG. 4 is a graph showing an example in which the expression level (MMP1 mRNA expression level) of the gene represented by SEQ ID NO: 23 in the sequence listing was measured in head and neck cancer metastatic lymph nodes and normal lymph nodes.
- FIG. 5 is a graph showing an example of the results of detecting ANXA8L and DSG3 gene mRNA by RT-PCR for 8 specimens of CK19 mRNA-negative head and neck cancer metastatic lymph nodes.
- FIG. 6 is a graph showing an example of the results of detecting ANXA8L and DSG3 gene mRNA by RT-PCR method for 7 metastasis-negative specimens and 12 metastasis-positive specimens.
- FIG. 7 is a graph showing an example of the results of detection of mRNA for KRT-1, KRT-6A, MMP1, S100P, and ARSI genes by RT-PCR for metastasis-negative 7 specimens and metastasis-positive 12 specimens.
- the present invention compares the total gene expression levels of head and neck squamous cell carcinoma metastatic cervical lymph nodes and non-cancer-bearing patient-derived cervical lymph nodes (both human cervical lymph nodes). 36 types of genes shown in Table 1 identified as genes whose expression is upregulated and whose expression is not detected in salivary glands can be used as tumor markers indicating the possibility of metastasis of cervical cancer to cervical lymph nodes. Based on this knowledge.
- cervical lymph node derived from a non-cancer-bearing patient refers to a cervical lymph node provided from a patient with a benign disease (not cancer) that has undergone cervical surgery.
- a cervical lymph node derived from a non-cancer-bearing patient can show a gene expression state of a cervical lymph node (ie, a normal cervical lymph node) to which cancer has not spread. Therefore, in the cervical lymph nodes where head and neck cancer has metastasized, genes that show higher expression levels than those in non-cancer-bearing patient-derived cervical lymph nodes may cause metastasis of cervical cancer to cervical lymph nodes.
- Table 1 The 36 genes shown in Table 1 below satisfy this condition.
- salivary gland cells are often cells in the cervical lymph nodes. Therefore, a gene whose expression is detected in the salivary gland may cause false positives of a gene that commonly shows increased expression only in cancer metastatic cervical lymph nodes. Since the 36 genes shown in Table 1 below are not detected in salivary glands, these genes can be used as tumor markers with a reduced risk of false positive. Among these, ANXA8L2, DSG3, KRT1, KRT6A, ARSI, MMP1 and S100P are preferable as a gene used as a tumor marker from the viewpoint of detection sensitivity of metastasis and false positive reduction.
- ANXA8L2 KRT1, KRT6A, ARSI, MMP1 And S100P are more preferable, and ANXA8L2 is more preferable.
- the DSG3 gene is also called a PVA gene (the same applies hereinafter).
- the present invention is a method for analyzing metastasis of head and neck cancer to a cervical lymph node (hereinafter also referred to as “analysis method of the present invention”), which is arranged in a cervical lymph node sample.
- Cervical lymph node metastasis comprising measuring the expression level of at least one gene selected from the group consisting of the genes represented by SEQ ID NOs: 1-36 in the column table and comparing the expression level with a reference value It relates to the analysis method.
- the expression level of at least one gene selected from the group consisting of the genes represented by SEQ ID NOs: 1 to 8 and 10 to 36 in the sequence listing in the cervical lymph node sample is used.
- Examples include a method for analyzing cervical lymph node metastasis, which comprises measuring and comparing the expression level with a reference value.
- head and neck cancer refers to cancer that can be formed from the neck excluding the brain and eyes.
- oral cancer nasal sinus cancer, lip cancer, pharyngeal cancer, laryngeal cancer, head Includes tumors and ear cancer.
- tumor marker is a generic name for substances that serve as markers (markers) of cancer cells and are useful as criteria for diagnosis and treatment of cancer.
- “measuring the expression level of a gene” means measuring the amount of a gene expression product.
- the “expression product” includes an RNA component contained in total RNA extracted from a cell, and may include a transcription product (mRNA) of a gene.
- the method for measuring the gene expression level is not particularly limited, and can be performed, for example, by a quantitative PCR method or a DNA microarray method.
- the gene expression level may be relative to the internal standard, or relative to the sample to be compared (for example, a normal cell sample).
- the gene to be measured refers to the gene shown in Table 1 above (the genes represented by SEQ ID NOs: 1 to 36 in the Sequence Listing) unless otherwise specified.
- cervical lymph node sample refers to a lymph node to be analyzed for the presence or absence of metastasis of head and neck cancer, for example, sentinel lymph node, and surroundings where head and neck cancer is present or present. Other cervical lymph nodes, and lymph nodes removed by cervical dissection.
- total RNA is recovered from the entire lymph node recovered from the subject, cDNA or cRNA is prepared, and quantitative PCR method or DNA microarray is used using them. It is preferable to carry out the method.
- comparing the expression level with a reference value means comparing the expression level in an analysis sample with a preset reference value.
- the reference value can be the expression level in normal cervical lymph nodes.
- the reference value is preferably 3 times or more, more preferably 10 times or more, even more preferably 30 times or more, even more preferably 100 times or more higher than the reference value, the neck of the sample It is possible that head and neck cancer has spread to lymph nodes.
- the reference value is preferably 3 times or more, more preferably 10 times or more, still more preferably 30 times or more, and even more preferably 100 times or more of the expression level in normal cervical lymph nodes. be able to.
- the expression level of the sample is higher than a reference value, it can be considered that there is a high possibility that head and neck cancer has spread to the cervical lymph node of the sample.
- normal cervical lymph nodes can include cervical lymph nodes of normal human individuals, but it is ethically difficult to remove the lymph nodes of a completely healthy person. Therefore, in the present specification, the “normal cervical lymph node” is a cervical lymph node provided from a patient with a benign disease (not cancer) that has undergone cervical surgery. Lymph node ".
- the number of genes whose expression levels are measured / compared may be one, but from the viewpoint of analysis accuracy, two or more are preferable, five or more are more preferable, and ten or more are more preferable. More preferably, 20 or more types are even more preferable.
- cervical dissection that is, removal of all lymph nodes (about 30) present in the cervix is generally performed.
- the analysis method of the present invention to these isolated cervical lymph nodes, it is possible to clarify how many lymph node metastases existed in the cervix, and the number of the lymph node metastasis can be determined according to the number of the lymph nodes. Can be considered and determined.
- the analysis method of the present invention can also be applied to a method of performing dissection (sentinel lymph node biopsy).
- the determination of head and neck cancer metastasis to a human lymph node for medical purposes, and the presence or absence of head and neck cancer metastasis to a human lymph node for medical purposes. Does not include judging prescriptions and treatment / surgical plans.
- the analysis method of the present invention determines the metastasis of head and neck cancer to human lymph nodes for medical purposes, and the method of determining head and neck cancer metastasis to human lymph nodes for medical purposes. It may include determining a prescription and a treatment / surgical plan based on the presence or absence.
- the present invention provides a head and neck comprising one or a plurality of genes selected from the group consisting of genes represented by SEQ ID NOs: 1-36 in the sequence listing, or their expression products and / or expression levels.
- the present invention relates to a tumor marker for head cancer (hereinafter also referred to as “tumor marker for head and neck cancer of the present invention”).
- the expression product may include an RNA strand transcribed using gene DNA as a template, that is, an RNA strand synthesized by RNA polymerase, and an RNA strand modified in a cell after transcription.
- the RNA strand contained in the expression product is not particularly limited.
- RNA messenger RNA
- rRNA ribosomal RNA
- tRNA transport RNA
- snRNA nuclear low molecular RNA
- SnoRNA nucleolar low molecular RNA
- the tumor marker for head and neck cancer of the present invention can be used as an index of head and neck cancer metastasis in the cervical lymph node. That is, when the expression of the tumor marker for head and neck cancer of the present invention is enhanced in the cervical lymph node, the possibility that metastasis has occurred in the lymph node is increased. Therefore, in one embodiment, the tumor marker for head and neck cancer of the present invention comprises a transcript of a gene selected from the group consisting of genes represented by SEQ ID NOs: 1 to 36 in the sequence list of head and neck cancer, It is a tumor marker of head and neck cancer for use in the analysis method of the invention.
- the tumor marker for head and neck cancer of the present invention is at least one selected from the group consisting of genes represented by SEQ ID NOs: 1 to 8 and 10 to 36 in the sequence list of head and neck cancer.
- a tumor marker for head and neck cancer which comprises a gene transcription product and is used in the analysis method of the present invention.
- the present invention provides, as a further aspect, the use of the tumor marker of the present invention, which comprises analyzing or determining or determining the metastasis of head and neck cancer in a cervical lymph node or a head and neck lymph node sample. Regarding tumors.
- One embodiment thereof includes the use of the tumor marker of the present invention in the analysis method of the present invention.
- Example 1 Metastatic lymph nodes (7 cases) derived from patients with head and neck squamous cell carcinoma were used as samples. Moreover, the lymph node (1 example) and salivary gland (5 examples) derived from a non-cancer bearing patient were used as a comparison object sample. Regarding the use of specimens in this study, written consent was obtained after sufficient explanation was given to the patient and family.
- [Use of tumor marker] The expression level of mRNA of SEQ ID NOs: 6, 9, 13, and 23 (ANXA8L2, DSG3 (PVA), S100P, and MMP1 genes, respectively) in the sequence listing was changed to 9 samples of head and neck squamous cell carcinoma metastatic lymph nodes. The expression level was compared with the expression level in normal lymph nodes (lymph nodes derived from non-cancer-bearing patients). The expression level was measured by the real-time quantification RT-PCR method. That is, 100 ng of TOTAL RNA derived from each lymph node tissue was used as a template, and each mRNA was reverse transcribed and amplified by Light Cycler (Roche Diagnostics) using specific primers.
- the expression level of each gene was quantified by detecting the amount of amplified product using TaqMan (registered trademark) probe (Applied Biosystems) or SYBR (registered trademark) Green I (Takara, Otsu, Japan).
- the four genes show expression levels exceeding the expression levels in normal lymph node samples in all head and neck squamous cell carcinoma metastasis lymph node samples, and the four genes represent one sample. All of the head and neck squamous cell carcinoma metastasized lymph node samples except the above showed an expression level exceeding 3 times the expression level in the normal lymph node sample.
- Example 2 Eight lymph node specimens whose metastasis was determined to be negative in a conventional cancer metastasis gene test for detection of Cytokeratin 19 (CK19) mRNA but whose head and neck cancer had metastasized by microscopic pathological examination Used as a sample. Regarding the use of specimens in this study, written consent was obtained after giving sufficient explanations to the patient and family.
- CK19 Cytokeratin 19
- [Use of tumor marker] The expression level of mRNA of the genes of SEQ ID NOs: 6 and 9 in the sequence listing (respectively ANXA8L2 and DSG3 (PVA) genes) was measured for the sample, and the expression level was measured for normal lymph nodes (lymph nodes derived from non-cancer-bearing patients). ) And the expression level in The expression level was measured by the real-time quantification RT-PCR method as in Example 1.
- Example 3 A new metastatic lymph node (12 cases) derived from a patient with squamous cell carcinoma of the head and neck different from Examples 1 and 2 was used as a sample, and a new lymph node (7 cases) derived from a non-cancer-bearing patient was used as a comparative sample. Using. Regarding the use of specimens in this study, written consent was obtained after sufficient explanation was given to the patient and family.
- the expression level was measured for the sample, and the expression level was compared with the expression level in the comparative sample.
- the expression level was measured by the real-time quantification RT-PCR method as in Example 1.
- FIGS. 6 and 7 The results are shown in FIGS.
- the expression of ANXA8L2 and DSG3 (PVA) genes was not observed at all in normal lymph nodes.
- FIG. 7 the expression of KRT-1, KRT-6A, MMP1, S100P, and ARSI genes was also significantly increased in metastatic lymph nodes compared to normal lymph nodes.
- the present invention is useful, for example, in the field of head and neck cancer treatment.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
すなわち、本発明は、1つの態様として、頸部リンパ節への頭頸部癌の転移を分析する方法(以下、「本発明の分析方法」ともいう)であって、頸部リンパ節試料における配列表の配列番号1~36で表される遺伝子からなる群から選択される少なくとも1つの遺伝子の発現量を測定すること、及び、前記発現量を基準値と比較することを含む頸部リンパ節転移分析方法に関する。
本発明は、その他の態様として、配列表の配列番号1~36で表される遺伝子からなる群から選択される1若しくは複数の遺伝子、又は、それ若しくはそれらの発現産物及び又は発現量からなる頭頸部癌の腫瘍マーカー(以下、「本発明の頭頸部癌の腫瘍マーカー」ともいう)に関する。前記発現産物は、遺伝子のDNAを鋳型として転写されるRNA鎖、すなわち、RNAポリメラーゼにより合成されるRNA鎖、及び、転写後細胞内で修飾されたRNA鎖を含みうる。前記発現産物に含まれるRNA鎖は、特に制限されず、例えば、メッセンジャーRNA(mRNA)、リボソームRNA(rRNA)、運搬RNA(tRNA)、核内低分子RNA(snRNA)、核小体低分子RNA(snoRNA)、及びその他のタンパク質を指令しないRNA等が挙げられる。これらのRNA鎖は、転写後、細胞内でプロセッシングされたものも含む。また、本明細書において、「遺伝子」とは、生体機能と関連するDNAの任意の断片をいう。なお、配列表のポリヌクレオチドがRNAを表す場合、t(チミン)塩基は、u(ウラシル)塩基に読み替えるものとする。
[試料]
頭頸部扁平上皮癌患者由来の転移リンパ節(7例)を試料とした。また、比較対象試料として非担癌患者由来のリンパ節(1例)及び唾液腺(5例)を用いた。なお、検体の本研究への使用については、患者本人及び家族へ十分な説明を行った上で、文書による同意を得た。
各試料を機械的にホモジナイズした後、Isogen(Nippon Gene, Toyama, Japan)を用いてトータルRNAを抽出、精製した。トータルRNA1μgをケミルミネッセントRT-IVTラベリングキット(Applied Biosystems, FosterCity, CA)を用いて増幅し、digoxigenin(Roche Diagnostics, Basel, Switzerland)標識cRNAを合成した。合成cRNAをヒトゲノムサーベイマイクロアレイ(Applied Biosystems)にハイブリダイゼーションさせたのち、ケミルミネッセントディテクションキット(Applied Biosystems)を用いて洗浄、発色後、Applied Biosystems 1700マイクロアレイアナライザー(Applied Biosystems)を用いて29,098遺伝子の発現定量を行った。各症例の遺伝子発現量の比較はGene Spring GX7.3(Agilent Technologies, SantaClara, CA)を用いて解析した。
頭頸部扁平上皮癌転移リンパ節7検体と非担癌患者由来リンパ節1検体の全遺伝子発現量を比較した。非転移リンパ節と比較して、転移リンパ節においてのみ共通して3倍以上の発現亢進が認められ、かつ唾液腺において発現が検出されない遺伝子を腫瘍マーカーとして36種類同定した(上記表1、配列表の配列番号1~36で表される遺伝子)。各遺伝子における発現亢進の度合いを上記表1において「変化倍率」として示す。同定されたRefSeqあるいはUniGeneに登録されていない新規遺伝子が2種類認められ(配列表の配列番号8及び12で表される遺伝子)、また癌との関連が報告されている遺伝子が12種類含まれていた。
配列表の配列番号6、9、13、及び23の遺伝子(それぞれ、ANXA8L2、DSG3(PVA)、S100P、MMP1遺伝子)のmRNAの発現量を、新たな9サンプルの頭頸部扁平上皮癌転移リンパ節について測定し、その発現量を正常リンパ節(非担癌患者由来のリンパ節)における発現量と比較した。発現量の測定は、リアルタイム定量化RT‐PCR法にて行った。すなわち、各リンパ節組織由来TOTAL RNA 100 ngを鋳型とし、それぞれのmRNAを特異的なプライマーを用いてLight Cycler(Roche Diagnostics)にて逆転写及び増幅した。同時に、TaqMan(登録商標)プローブ(Applied Biosystems)又はSYBR(登録商標)Green I(Takara, Otsu, Japan)を用いて増幅産物量を検出することにより各遺伝子の発現量を定量した。
[試料]
Cytokeratin19(CK19)mRNAを検出対象とした従来のがん転移遺伝子検査では転移が陰性と判断されたが、顕微鏡による病理組織検査によって頭頸部癌が転移していたことが判明したリンパ節8検体を試料として用いた。なお、検体の本研究への使用については、患者本人及び家族へ十分な説明を行った上で、文書による同意を得た。
配列表の配列番号6及び9の遺伝子(それぞれ、ANXA8L2及びDSG3(PVA)遺伝子)のmRNAの発現量を、前記試料ついて測定し、その発現量を正常リンパ節(非担癌患者由来のリンパ節)における発現量と比較した。発現量の測定は、前記実施例1と同様にリアルタイム定量化RT‐PCR法にて行った。
[試料]
実施例1及び2とは異なる新たな頭頸部扁平上皮癌患者由来の転移リンパ節(12例)を試料とし、また、比較対象試料として新たな非担癌患者由来のリンパ節(7例)を用いた。なお、検体の本研究への使用については、患者本人及び家族へ十分な説明を行った上で、文書による同意を得た。
配列表の配列番号6、9、4、2、23、13、及び32の遺伝子(それぞれ、ANXA8L、DSG3(PVA)、KRT-1、KRT-6A、MMP1、S100P、及びARSI遺伝子)のmRNAの発現量を、前記試料ついて測定し、その発現量を比較対象試料における発現量と比較した。発現量の測定は、前記実施例1と同様にリアルタイム定量化RT‐PCR法にて行った。
Claims (5)
- 頸部リンパ節への頭頸部癌の転移を分析する方法であって、
頸部リンパ節試料における、配列表の配列番号1~8及び10~36で表される遺伝子からなる群から選択される少なくとも1つの遺伝子の発現量を測定すること、及び、
前記発現量を基準値と比較することを含む、頸部リンパ節転移分析方法。 - 基準値が正常頸部リンパ節における発現量であって、前記試料の発現量が基準値よりも3倍以上高い場合に前記試料頸部リンパ節に頭頸部癌の転移している可能性が高いとする基準値である、請求項1記載の頸部リンパ節転移分析方法。
- 基準値が正常頸部リンパ節における発現量の3倍以上の量であって、前記試料の発現量が基準値よりも高い場合に前記試料頸部リンパ節に頭頸部癌の転移している可能性が高いとする基準値である、請求項1記載の頸部リンパ節転移分析方法。
- 前記遺伝子が、配列表の配列番号6で表されるANXA8L2遺伝子である、請求項1から3のいずれかに記載の頸部リンパ節転移分析方法。
- 配列表の配列番号1~8及び10~36で表される遺伝子からなる群から選択される1若しくは複数の遺伝子、又は、それ若しくはそれらの発現産物及び又は発現量からなり、請求項1から3のいずれかに記載の頸部リンパ節転移分析方法に用いる、頭頸部癌の腫瘍マーカー。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/518,656 US8715931B2 (en) | 2009-12-24 | 2010-12-22 | Method for analyzing cervical lymph node metastasis, and tumor marker for head and neck cancer |
EP10839453.7A EP2514835B1 (en) | 2009-12-24 | 2010-12-22 | Method for analyzing cervical lymph node metastasis, and tumor marker for head and neck cancer |
CN201080058541.XA CN102686745B (zh) | 2009-12-24 | 2010-12-22 | 颈部淋巴结转移分析方法及头颈癌的肿瘤标记物 |
JP2011547592A JP5807877B2 (ja) | 2009-12-24 | 2010-12-22 | 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009292611 | 2009-12-24 | ||
JP2009-292611 | 2009-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011078223A1 true WO2011078223A1 (ja) | 2011-06-30 |
Family
ID=44195750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/073129 WO2011078223A1 (ja) | 2009-12-24 | 2010-12-22 | 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー |
Country Status (5)
Country | Link |
---|---|
US (1) | US8715931B2 (ja) |
EP (1) | EP2514835B1 (ja) |
JP (1) | JP5807877B2 (ja) |
CN (1) | CN102686745B (ja) |
WO (1) | WO2011078223A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3004478A1 (en) * | 2015-11-06 | 2017-05-11 | University Of Southern California | Development of prognostic markers dsg-3 from the saliva of oral cancer patients |
CN113684242A (zh) * | 2021-09-01 | 2021-11-23 | 山东大学 | 一种基于淋巴结微生物菌群的头颈癌预后生物标志物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007000052A (ja) | 2005-06-22 | 2007-01-11 | Ehime Univ | 頭頸部癌の腫瘍マーカー |
JP2008505644A (ja) * | 2004-07-09 | 2008-02-28 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 |
WO2008044504A1 (fr) * | 2006-10-12 | 2008-04-17 | Niigata University | Procédé de diagnostic d'un cancer de la langue |
JP2009034071A (ja) | 2007-08-03 | 2009-02-19 | Ehime Univ | 頭頸部癌の腫瘍マーカー |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2094719A4 (en) * | 2006-12-19 | 2010-01-06 | Genego Inc | NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF |
CN101298628A (zh) | 2007-04-30 | 2008-11-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 与鼻咽癌的发生和淋巴结转移相关的mdm2基因多态性及其检测方法 |
CN101329350A (zh) | 2007-06-21 | 2008-12-24 | 许洋 | 检测鼻咽癌特征蛋白的优化质谱模型及其制备方法和应用 |
JP2011508598A (ja) * | 2008-01-04 | 2011-03-17 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク | 乳癌のインビトロ分子診断 |
-
2010
- 2010-12-22 CN CN201080058541.XA patent/CN102686745B/zh not_active Expired - Fee Related
- 2010-12-22 US US13/518,656 patent/US8715931B2/en not_active Expired - Fee Related
- 2010-12-22 WO PCT/JP2010/073129 patent/WO2011078223A1/ja active Application Filing
- 2010-12-22 JP JP2011547592A patent/JP5807877B2/ja active Active
- 2010-12-22 EP EP10839453.7A patent/EP2514835B1/en not_active Not-in-force
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008505644A (ja) * | 2004-07-09 | 2008-02-28 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 食道癌、結腸癌、頭頸部癌、およびメラノーマにおけるマーカーの同定 |
JP2007000052A (ja) | 2005-06-22 | 2007-01-11 | Ehime Univ | 頭頸部癌の腫瘍マーカー |
WO2008044504A1 (fr) * | 2006-10-12 | 2008-04-17 | Niigata University | Procédé de diagnostic d'un cancer de la langue |
JP2009034071A (ja) | 2007-08-03 | 2009-02-19 | Ehime Univ | 頭頸部癌の腫瘍マーカー |
Non-Patent Citations (15)
Title |
---|
FERRIS L. ROBERT ET AL., CANCER RES., vol. 65, no. 6, 2005, pages 2147 - 2156 |
HAMAKAWA H; FUKUZUMI M ET AL.: "Genetic detection of micrometastases based on SCC antigen mRNA in cervical lymph nodes of head and neck cancer", CLIN EXP METASTASIS, vol. 17, 1999, pages 593 - 599 |
HAMAKAWA H; TAKEMURA K ET AL.: "Histological study on pN upgrading of oral cancer", VIRCHOWSARCH, vol. 437, 2000, pages 116 - 121 |
HIROYUKI GODA ET AL.: "Kokugan Sentinel Lymph- setsu Seiken eno OSNA-ho no Oyo to Mondaiten, OS036-5", DAI 45 KAI JAPAN SOCIETY OF CLINICAL ONCOLOGY SOKAI SHOROKUGO, vol. 42, no. 2, 20 September 2007 (2007-09-20), pages 436 * |
HIROYUKI HAMAKAWA ET AL.: "Genetic Diagnosis for Micrometastasis of Oral Cancer", JOURNAL OF THE JAPANESE STOMATOLOGICAL SOCIETY, vol. 50, no. 3, May 2001 (2001-05-01), pages 145 - 154 * |
HIROYUKI HAMAKAWA ET AL.: "Genetic Diagnosis of Oral Cancer", J. HARD TISSUE BIOLOGY, vol. 14, no. 2, 2005, pages 163 - 165 * |
HIROYUKI HAMAKAWA: "Carcinoma of oral cavity. New diagnosis and treatment", RINSHO TO KENKYU, vol. 82, no. 7, July 2005 (2005-07-01), pages 1201 - 1205 * |
KIHARA K; KONO N ET AL.: "Study of sentinel lymph node biopsy in NO oral cancer", HEAD AND NECK CANCER, vol. 28, pages 108 - 113 |
MATSUZUKA T; KANO M ET AL.: "A suggested method for lymphatic mapping in squamous cell carcinoma of the head and neck", HEAD AND NECK CANCER, vol. 27, 2001, pages 192 - 197 |
MORTON D; WEN DR ET AL.: "Technical details of intraoperative lymphatic mapping for early stage melanoma", ARCH SURG, vol. 127, 1992, pages 392 - 399, XP000610674 |
NAKASHIRO K; SHINTANI S; OHNISHIA; TERAKADO N; HAMAKAWA H: "Intraoperative rapid detection of micrometastasis in sentinel lymph nodes of oral malignant tumors", HEAD AND NECK CANCER, vol. 29, 2003, pages 64 - 69 |
OHNISHI A: "Genetic diagnosis of micrometastasis of oral cancer to cervical lymph node by use of realtime quantitative PCR method", EHIME MEDICAL JOURNAL, vol. 21, 2002, pages 183 - 191 |
ROBERT L. FERRIS ET AL.: "Molecular Staging of Cervical Lymph Nodes in Squamous Cell Carcinoma of the Head and Neck", CANCER RES, vol. 65, no. 6, 2005, pages 2147 - 2156, XP002477565, DOI: doi:10.1158/0008-5472.CAN-04-3717 * |
SATOH K; HIRAYAMA H ET AL.: "Sentinel lymph node biopsy using technetium 99m labeled tin colloids in breast cancer", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 192, 2000, pages 147 - 150 |
See also references of EP2514835A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20120270218A1 (en) | 2012-10-25 |
JP5807877B2 (ja) | 2015-11-10 |
EP2514835A1 (en) | 2012-10-24 |
CN102686745B (zh) | 2014-01-29 |
CN102686745A (zh) | 2012-09-19 |
JPWO2011078223A1 (ja) | 2013-05-09 |
EP2514835B1 (en) | 2013-07-17 |
EP2514835A4 (en) | 2012-11-28 |
US8715931B2 (en) | 2014-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101970692B (zh) | 使用肺癌特异性甲基化标记基因检测肺癌的方法 | |
Weigelt et al. | Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers | |
US20150191793A1 (en) | Molecular markers for prognostically predicting prostate cancer, method and kit thereof | |
AU2013281355B2 (en) | Targeted RNA-seq methods and materials for the diagnosis of prostate cancer | |
JP2017532959A (ja) | Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム | |
JP2008510454A (ja) | 肺癌および乳癌におけるマーカーの同定 | |
EP3299478A1 (en) | Methods for predicting drug responsiveness in cancer patients | |
JP2017508442A (ja) | Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー | |
US20150005184A1 (en) | Diagnosis of melanoma by nucleic acid analysis | |
ES2947946T3 (es) | Métodos para predecir el riesgo de metástasis en melanoma cutáneo | |
CN106676191B (zh) | 一种用于结肠腺癌的分子标志物 | |
CN111269985B (zh) | hsa_circRNA6448-14在食管鳞癌诊断以及预后预测中的应用 | |
JP5807877B2 (ja) | 頸部リンパ節転移分析方法及び頭頸部癌の腫瘍マーカー | |
JP6949315B2 (ja) | 肺扁平上皮癌と肺腺癌の鑑別評価方法 | |
EP3810807A1 (en) | Methods and compositions for the analysis of cancer biomarkers | |
JP4967112B2 (ja) | 頭頸部癌の腫瘍マーカー | |
JP2007082433A (ja) | 悪性脳腫瘍マーカー遺伝子およびその用途 | |
CN116075598A (zh) | 用于鉴定人类受试者的医学病状的方法 | |
CN110982901B (zh) | 用于侵袭性甲状腺乳头状癌诊断的循环环状rna标志物及应用 | |
CN113637758B (zh) | miR-19b/miR-26a作为标志物在制备恶性间皮瘤检测试剂盒中的应用 | |
WO2007088971A1 (ja) | がん予後判定に利用できる遺伝子群 | |
WO2023004460A1 (en) | Methods of detecting and/or diagnosing pancreatic cancer | |
JP2011036242A (ja) | miRNA発現プロファイリングに基づく尿路上皮癌の検出方法 | |
CN109536613A (zh) | Linc01767在肝细胞癌中的应用 | |
Singaraju et al. | Role of advanced diagnostic aids in oral pathology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080058541.X Country of ref document: CN |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10839453 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011547592 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13518656 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010839453 Country of ref document: EP |